EGFR and non-small cell lung carcinoma: Simultaneously, a similar phase II study reported no statistically significant difference in PFS between Olaparib in combination with gefitinib and gefitinib monotherapy as first-line therapy for patients with EGFR-mutant NSCLC (12).